Loading company
ONCBeone Medicines Ltd.$48BA+Built from Evommune, Inc.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
The themes Evommune is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
$8.65+10.3%Nov 11 close
The latest quarter (ended September 30, 2026) is from Evommune’s earnings press release of November 12, 2026. It will be replaced by the official quarterly report (10-Q) once Evommune files it.
Grade D-
The band under the price shows the grade on each date, built only from filings that were public by then.
